All In Biotech

Drug Trial Radar · NCT06977724

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 26, 2025

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement and Rheumatoid arthritis (RA) is a long-lasting autoimmune disease that causes the body's immune system to attack itself. RA targets the body's joints, causing inflammation (swelling, pain, and redness). ABBV-319 exhibits potential B cell depletion in SLE, SjD and RA which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE, SjD and RA. ABBV-319 is an investigational drug being developed for the treatment of SLE , SjD and RA. Participants are placed in 1 of 8 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE, SjD or RA. Around 48 adult participants with SLE, SjD or RA will be enrolled at approximately up to 17 sites worldwide. Participants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Dry Eye Syndrome
  • Systemic Lupus Erythematosus

Interventions

  • ABBV-319Drug

    Intravenous (IV) Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 400 days
  2. Change from Baseline in B Cells in Blood and TissueTime frame: Up to approximately 400 days
  3. Maximum Plasma Concentration (Cmax) of ABBV-319Time frame: Up to approximately 400 days
  4. Time to Cmax (Tmax) of ABBV-319Time frame: Up to approximately 400 days
  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-319Time frame: Up to approximately 400 days
  6. Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-319Time frame: Up to approximately 400 days
  7. Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-319Time frame: Up to approximately 400 days
  8. Percentage of Participants with Detection of Neutralizing Antibodies (nAbs) for ABBV-319Time frame: Up to approximately 400 days

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Life Clinical Trials - Colonial Drive - Margate /ID# 276050

    Margate, Florida · Recruiting

  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836

    Tampa, Florida · Recruiting

  • Advanced Quality Medical Research /ID# 278462

    Orland Park, Illinois · Recruiting

  • Private Practice - Dr. Ramesh C. Gupta /ID# 275826

    Memphis, Tennessee · Recruiting

  • Integrative Rheumatology of South Texas - Harlingen /ID# 276458

    Harlingen, Texas · Recruiting

  • Les Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre /ID# 272692

    Strasbourg, Alsace, France · Recruiting

  • CHU de Montpellier - Hopital Saint Eloi /ID# 279892

    Montpellier, Herault, France · Recruiting

  • Universitair Medisch Centrum Utrecht /ID# 273398

    Utrecht, Netherlands · Recruiting

  • Amsterdam University Medical Center /ID# 274286

    Amsterdam, North Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.